A trials attorneys’ group not only argues that an industry estimate of the cost increases that would be prompted by the generic labeling rule was calculated incorrectly, it also says that even if that increase actually occurred, consumers largely would not stop buying the products.
The American Association for Justice’s critique of a Generic Pharmaceutical Association-sponsored study likely is intended in part to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?